⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29192004 | 0.81 | CPB2 (0.43) | — | |
| Water SCHEMBL29192003 | 0.81 | CPB2 (0.43) | — | |
| SCHEMBL29113992 | 0.80 | TBXAS1 (0.40) | — | |
| Bromide SCHEMBL29192001 | 0.80 | CPB2 (0.42) | — | |
| SCHEMBL5533170 | 0.79 | RPS6KB1 (0.38) | — | |
| SCHEMBL24128290 | 0.76 | TBXAS1 (0.38) | — | |
| SCHEMBL3708433 | 0.73 | RAB9A (0.49) | — | |
| SCHEMBL26038699 | 0.73 | CPB2 (0.37) | — | |
| SCHEMBL4298196 | 0.73 | ALDH1A1 (0.39) | — | |
| SCHEMBL13684790 | 0.72 | CPB2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| WO-2024044713-A1 | NAPHTHYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES | ENLIVEN INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4227299-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| EP-4227299-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| CN-116348464-A | Benzimidazolone GLP-1 receptor agonists and uses thereof | 杭州中美华东制药有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-4161494-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022078152-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-04-21 | — | — | WO | disclosed |
| WO-2022078152-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-04-21 | — | — | WO | disclosed |